Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 63

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 63
---
 various countries, business closures or business disruptions
and the effectiveness of actions taken to contain and treat the disease. If we or any of the third parties with whom we engage were to
experience shutdowns, undergo the compulsory universal testing by the HKSAR Government or other business disruptions, our ability to conduct
our business in the manner and on the timelines presently planned could be materially and negatively impacted.

In addition, the trading prices
for our Class A Ordinary Shares and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic.
As a result, we may face difficulties raising capital through sales of our securities or such sales may be on unfavorable terms.

The outbreak of the novel coronavirus disease,
COVID-19, or other pandemic, epidemic or outbreak of an infectious disease may materially and adversely impact our preclinical studies
and clinical trials.

As a result of the COVID-19
outbreak, or similar pandemics, we have and may in the future experience disruptions that could materially and adversely impact our manufacturing,
preclinical development activities, preclinical studies and planned clinical trial. Potential disruptions include but are not limited
to:

  delays or difficulties in enrolling patients in our clinical trials, should the relevant clinical trials be approved;  

  delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site st...  

  increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;  

  diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of...  

  interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by governments, employers and others or interrupt...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for regulatory submission and trial initiation;  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  interruption or delays in our CROs and collaborators meeting expected deadlines or complying with regulatory requirements related to preclinical development activities, preclinical studies and ...  

  delays or disruptions in preclinical experiments and investig